
In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.
Philip J. Ferrone, MD, is partner with Vitreoretinal Consultants of New York and professor of ophthalmology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.